Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate.

CONCLUSION: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months. PMID: 31371650 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31371650?dopt=Abstract

Source: J Rheumatol - July 31, 2019 Category: Rheumatology Authors: Jani M, Chinoy H, Barton A, OUTPASS Tags: J Rheumatol Source Type: research